We treated melanoma with gal-3 inhibitor and PD-L1 inhibitor, which exhibited a superior effect than separate treatment in suppression of tumor development (Fig. 7, Supplementary Fig. 9), consistent with the previous studies on tumor therapy by inhibiting gal-3 and immune checkpoint synchronously [45]. The gene discussed is LGALS3; the disease is neoplasm.